1. Isotope-Labeled Compounds
  2. Isotope-Labeled Inhibitors

Isotope-Labeled Inhibitors

Isotope-Labeled Inhibitors (2081):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15162A
    MMAE-d8 2070009-72-0 99.29%
    D8-MMAE (D8-Monomethyl auristatin E) is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
    MMAE-d8
  • HY-19939S
    VX-984 1476074-39-1 99.20%
    VX-984 is a potent DNA-PK inhibitor.
    VX-984
  • HY-13631AS
    Exatecan-d5 mesylate 99.77%
    Exatecan D5 mesylate (DX8951f-D5) is deuterium labeled Exatecan Mesylate. Exatecan mesylate is a DNA topoisomerase I inhibitor, with an IC50 of 0.975 μg/mL.
    Exatecan-d5 mesylate
  • HY-131968
    BMS-986202 1771691-34-9 99.46%
    BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research.
    BMS-986202
  • HY-15579AS
    MMAF-d8 hydrochloride 98.97%
    D8-MMAF hydrochloride is a deuterated form of MMAF hydrochloride, which is a microtubule disrupting agent.
    MMAF-d8 hydrochloride
  • HY-18300S
    Filgotinib-d4 2041095-50-3
    Filgotinib-d4 (GLPG0634-d4) is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
    Filgotinib-d4
  • HY-142283
    Dosimertinib 2403760-70-1
    Dosimertinib is a highly potent, selective, and orally efficacious deuterated EGFR targeting clinical candidate for the treatment of non-small-cell lung cancer.
    Dosimertinib
  • HY-145562
    Deucrictibant 2340111-58-0
    Deucrictibant is a potent bradykinin receptor antagonist. Bradykinin receptors are cell surface, G-protein coupled receptors of the seven-transmembrane domained family.
    Deucrictibant
  • HY-10201S
    Sorafenib-d3 1130115-44-4 99.08%
    Sorafenib-d3 (Bay 43-9006-d3) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
    Sorafenib-d3
  • HY-13631DS
    Dxd-d5
    Dxd-D5 (Exatecan-D5 derivative for ADC) is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .
    Dxd-d5
  • HY-104077S
    Remdesivir-d5 99.58%
    Remdesivir-D5 (GS-5734-D5) is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro.
    Remdesivir-d5
  • HY-B0421S
    Mycophenolic acid-d3 1185242-90-3 98.96%
    Mycophenolic acid D3 (Mycophenolate D3) is deuterium labeled Mycophenolic acid, which is an an immunosuppresant drug and has potent anti-proliferative activity.
    Mycophenolic acid-d3
  • HY-B0113S
    Omeprazole-d3 922731-01-9 98.99%
    Omeprazole D3 (H 16868 D3) is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.
    Omeprazole-d3
  • HY-B0801S
    Fexofenadine-d6 548783-71-7 99.28%
    Fexofenadine D6 (MDL-16455 D6) is deuterium labeled is Fexofenadine, which is an antihistamine pharmaceutical agent.
    Fexofenadine-d6
  • HY-15772S
    Osimertinib-d6 1638281-44-3 99.70%
    Osimertinib D6 (AZD-9291 D6) is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
    Osimertinib-d6
  • HY-15777AS
    Ribociclib-d6 hydrochloride 98.37%
    Ribociclib D6 (LEE011 D6) hydrochloride is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
    Ribociclib-d6 hydrochloride
  • HY-113468AS
    3-O-Methyldopa-d3 586954-09-8 99.34%
    3-O-Methyldopa D3 (3-Methoxy-L-tyrosine D3) is deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine.
    3-O-Methyldopa-d3
  • HY-50767S
    Palbociclib-d8 1628752-83-9 99.84%
    Palbociclib D8 (PD 0332991 D8) is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research.
    Palbociclib-d8
  • HY-110228
    Metformin-d6 hydrochloride 1185166-01-1 ≥98.0%
    Metformin D6 hydrochloride is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin hydrochloride triggers autophagy.
    Metformin-d6 hydrochloride
  • HY-133781S
    cis-Clopidogrel-MP derivative-13C,d3 98.50%
    cis-Clopidogrel-MP derivative-13C,d3 (Clopidogrel-MP-AM-13C,d3) is a 13C and deuterium labele cis-Clopidogrel-MP derivative. cis-Clopidogrel-MP derivative is a 3’-methoxyacetophenone derivative of Clopidogrel active metabolite. Clopidogrel is a well-known and orally active platelet inhibitor that targets P2Y12 receptor.
    cis-Clopidogrel-MP derivative-13C,d3